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Abstract
Three full-length genomic clones (pB19-M20, pB19-FL and pB19-HG1) of parvovirus B19 were produced in different laboratories. pB19-
M20 was shown to produce infectious virus. To determine the differences in infectivity, all three plasmids were tested by transfection and infection
assays. All three clones were similar in viral DNA replication, RNA transcription, and viral capsid protein production. However, only pB19-M20
and pB19-HG1 produced infectious virus. Comparison of viral sequences showed no significant differences in ITR or NS regions. In the capsid
region, there was a nucleotide sequence difference conferring an amino acid substitution (E176K) in the phospholipase A2-like motif of the VP1-
unique (VP1u) region. The recombinant VP1u with the E176K mutation had no catalytic activity as compared with the wild-type. When this
mutation was introduced into pB19-M20, infectivity was significantly attenuated, confirming the critical role of this motif. Investigation of the
original serum from which pB19-FL was cloned confirmed that the phospholipase mutation was present in the native B19 virus.
© 2008 Elsevier Inc. All rights reserved.Keywords: Parvovirus B19; PLA2-like motif; Infectious cloneIntroduction
Parvovirus B19 (B19V), a member of the genus Erythrovirus
of the family Parvoviridae, is a pathogenic virus distributed
worldwide in the human population (Young and Brown, 2004).
B19V is highly erythrotropic: infection of human erythroid
progenitor cells leads to cytotoxicity and interruption of eryth-
rocyte production (Mortimer et al., 1983). The physiological con-
ditions of the host and the extent of the immune antiviral response
then contribute to the evolution and clinical manifestation of the
infection (Young and Brown, 2004). Infection causes fifth disease⁎ Corresponding author. Bldg. 10/CRC, Rm. 3E5272 National Institutes of
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doi:10.1016/j.virol.2008.01.002in children (Anderson et al., 1985, 1983), polyarthropathy
syndrome in adults (Matsumura, 2001; Moore, 2000), transient
aplastic crisis in patients with underlying chronic hemolytic
anemia (Pattison et al., 1981; Serjeant et al., 1981), and chronic
anemia due to persistent infection in immunocompromised
patients (Kurtzman et al., 1989, 1988). Infection during pregnancy
can lead to hydrops fetalis with possible fetal loss (Kinney et al.,
1988) and/or congenital infection (Brown et al., 1993b).
In common with other parvoviruses, B19V has a small
(22 nm), nonenveloped, icosahedral capsid, encapsidating a
limited single-stranded DNA genome (5596 nucleotides (nt)).
The ends of the genome are long inverted terminal repeats (ITRs)
of 383 nt, of which the distal 365 nt forms an imperfect
palindrome (Deiss et al., 1990). Transcription of the B19 viral
genome is controlled by a single promoter (p6) located at map
unit 6, which regulates the synthesis of all nine viral transcripts
(Blundell et al., 1987; Ozawa et al., 1987). The single nonspliced
Fig. 1. Schematic representation of three full-length B19V genomic clones. The
three full-length B19V genomic clones, pB19-M20, pB19-FL and pB19-HG1,
were obtained from the B19V J35 isolate (GenBank Accession no. AY386330),
the NAN isolate (GenBank Accession no. AY504945) and the HV isolate
(GenBank Accession no. AF162273), respectively. The recombinant plasmids
were constructed using different plasmid vectors: pB19-M20, pPRoEX HTb
vector; pB19-FL, pLITMUS19 vector; and pB19-HG1, pUC18 vector. Arrows
indicate the genes in either B19V genome or vector, and shaded circles indicate
the ITR at both ends of B19V genome. Important restriction enzyme sites for
cloning and analyzing are labeled.
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combination of different splicing events, the other eight tran-
scripts encode the two capsid proteins (VP1 and VP2) and two
smaller proteins (7.5 kDa and 11 kDa) of yet unknown function
(Cotmore et al., 1986; Ozawa et al., 1987; St Amand et al.,
1991). In addition, a short open reading frame (ORF) putatively
encoding protein X is present in the VP1 region of the B19V
genome. The B19V NS protein is a multifunctional protein; in
addition to transregulation of the p6 promoter (Doerig et al.,
1990; Raab et al., 2002), NS contains motifs for nucleoside
triphosphate (NTP) binding and hydrolysis (Momoeda et al.,
1994) associated with helicase activity, suggesting a role of NS
in B19V DNA replication. Accumulating evidence also suggest
that the NTP-binding motif of NS is involved in the induction
of apoptosis in erythroid lineage cells during B19V infectionFig. 2. Alignment of amino acid sequences of VP1u regions of three full-length B19V
of pB19-M20 are shown with dashed lines. A boxed area indicates the PLA2-like
conserved catalytic residues and Ca2+-binding sites critical for enzymatic activity. Th
region of parvovirus B19 from the N terminus to C terminus.(Moffatt et al., 1998). The major capsid protein, VP2, which
comprises 95% of the capsid, is a 58-kDa protein. Earlier studies
showed that VP2 expressed in insect cells self-assembles into
virus-like particles (Kajigaya et al., 1991) and VP2 binds
directly to blood group P antigen, the cellular receptor of B19
virus (Brown et al., 1993a). The minor capsid protein, VP1,
differs from VP2 only in an N-terminal “unique region” (VP1u)
composed of an additional 227 amino acids. (Ozawa and Young,
1987). The VP1u region elicits a dominant immune response
(Saikawa et al., 1993; Rosenfeld et al., 1992; Ros et al., 2006)
and has phospholipase A2 (PLA2) activity, which is necessary
for B19V infection (Lu et al., 2006; Zadori et al., 2001). The two
small proteins, 7.5 kDa and 11 kDa, are encoded by the small,
abundant mRNAs of B19V and are unique among the parvo-
viruses characterized to date (Luo and Astell, 1993; St Amand
et al., 1991; St Amand and Astell, 1993). The 11-kDa protein
contains several proline-rich motifs that are conserved to Src
homology 3 (SH3) binding domain of eukaryotic proteins (Fan
et al., 2001). What functions the 11-kDa or 7.5-kDa protein play
in B19V replication and/or pathogenesis are unknown. We
previously defined the specific roles of these viral proteins in
B19Vinfectivity bymutagenesis analysis of the B19Vinfectious
clone (Zhi et al., 2004, 2006): null mutation of the NS and
VP1 proteins or deletion of the terminal hairpin sequence
completely abolished the viral infectivity, and a null mutant of
11-kDa protein was significantly attenuated (Zhi et al., 2004,
2006).
Three independent full-length clones (pB19-M20, pB19-FL
and pB19-HG1) have been produced in three different labora-
tories (Zhi et al., 2004, 2006). We have previously shown that
pB19-M20 produces infectious virus. However the other two full-
length clones (pB19-FL and pB19-HG1) have not been proven to
be infectious. In the present study, the infectivity of these full-
length clones was evaluated in parallel by transfection and infec-
tion assays.Mutagenesis analysis showed that a single amino acid
substitution (E176K) in the VP1u region of pB19-FL resulted in
loss of PLA2 activity and attenuation of viral infectivity.
Results
Cloning and sequencing analyses of full-length parvovirus B19
genomes
Three independent full-length clones (pB19-M20, pB19-FL
and pB19-HG1) were produced using different strategies (Fig. 1).genomic clones. Aligned positions of identical amino acids with the VP1u region
motif conserved among members of the Parvoviridae. Solid circles indicate
e numbers on the right indicate the positions of amino acid residues in the VP1u
Fig. 3. Comparison of infectivity of three full-length B19V genomic clones by RT-
PCR. Total RNAs were extracted from UT7/Epo-S1 cells at 72 h post-transfection
(hpt), or 0 and 72 h post-infection (hpi). PCR was performed with a primer pair of
B19-1 and B19-9. The products were analyzed by agarose gel electrophoresis. (+)
or (−) indicates the presence or absence of the reverse transcriptase in the reaction,
respectively. Numbers on the right indicate the respective amplicon sizes.
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Since pB19-M20 had been shown to produce infectious virus, it
was used for reference in the analyses of the DNA and protein
sequences. Although the hairpin sequences were similar to each
other among three B19V genomic clones, except for a deletion in
pB19-HG1 at nucleotide 193, the secondary configurations of the
hairpins in the palindromic regions were different: the hairpins in
pB19-HG1 and pB19-FL had flip/flip and flop/flip structures,
respectively, but the structures were flip/flop in pB19-M20.
Alignment of the primary amino acid sequences of the
proteins showed eighteen substitutions among the B19V genomic
clones (pB19-M20, pB19-FL and pB19-HG1) (Table 1). Fifteen
of them were found in the VP2, NS and11-kDa proteins, and the
putative X protein, but none were located in functionally impor-Fig. 4. Comparison of B19V replication following transfection of UT7/Epo-S1 cel
replication of B19V genome. (B) Southern blot analysis of B19 genome replication. D
Southern blotting after digestion with EcoRI (−) or BamHI (+) in order to investigate
agarose gel, transferred to a nylon membrane and hybridized with a 32P-random-pritant regions of the proteins (Ozawa et al., 1988; Fan et al., 2001).
Among the three mutations found in VP1 (Fig. 2), a nucleotide
point mutation (G3148A) of pB19-FL (corresponding to nt 3149
of pB19-M20) resulted in an amino acid substitution (E176K),
which is proximate to the catalytic residues of the PLA2-likemotif
in the VP1u region.
Production of infectious virus
We have previously shown that infectious virus was generated
from the cells transfected with plasmid pB19-M20 (Zhi et al.,
2004). In an attempt to determine if full-length clones pB19-FL
and pB19-HG1 were also able to produce infectious virus, we
used the supernatant prepared from the cell lysates of transfected
cells to infect UT7/Epo-S1 cells, and detected spliced transcripts
of viral capsid genes by RT-PCR as a marker for successful viral
infection. The spliced transcripts were present in all samples (Fig.
3) at 72 h post-transfection. Immediately after inoculation of the
clarified supernatant into the UT7/Epo-S1 cells, no RT-PCR
product was detected in any of the samples (Fig. 3), indicating that
there was no carry-over of the RNA from the transfected cells. At
72 h post-inoculation, spliced transcripts were detected in the
samples derived from the cells transfected with pB19-M20 or
pB19-HG1, but not with pB19-FL (Fig. 3); therefore both pB19-
M20 and pB19-HG1 were infectious, but the production of
infectious virus from the cells transfected with pB19-FL was
below the level of detection.
Excision of B19V genome from the plasmids after transfection
into permissive cells
During the replication of parvovirus B19, viral single-stranded
DNA is converted to a double-stranded replicative form whichls with full-length B19V genomic clones. (A) Schematic representation of the
NAwas extracted by the Hirt method at 72 h post-transfection and analyzed by
the presence of characteristic replicative forms. The fragments were separated by
med probe of the complete B19V genome.
Table 1
Comparison of amino acid sequences among proteins encoded by three B19V
full-length genomic clones
Protein
names
Position of
mutation a
Substitutions in three B19 full-length clones
pB19-m20
(J35 isolate)
PB19-FL
(NAN isolate)
PB19-FL
(HV isolate)
NS 57 L F F
71 A V V
11 F L L
183 T A T
205 F F I
526 F L F
558 P P S
VP1 14 E K K
107 D N N
176 E K E
377 C C S
574 T T P
VP2 150 C C S
347 T T P
7.5 kDa No change No change No change
11 kDa 7 D D G
10 M M T
54 I V V
X 51 A V A
a Positions and amino acid residues are described for each protein.
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minal region. These intermediate structures provide evidence for
viral DNA replication and can be distinguished by BamHI
restriction enzyme digestion (Fig. 4A). We performed Southern
blot analysis to test whether the lack of production of infectious
virus in pB19-FL was due to a defect in generation of progeny
viral DNA.
The UT7/Epo-S1 cells were transfected with the DNA frag-
ments containing full-length B19 genomes which were released
from the plasmids by restriction enzyme digestions. After trans-
fection, distinct doublets of 1.5 kb and 1.4 kb were detected in all
the transfected cell samples digested with BamHI, (Fig. 4B). This
result indicated that progeny viral DNA was generated from
the cells transfected with the three full-length clones, including
pB19-FL which was unable to produce infectious virus.
Viral capsid protein production
Viral capsid proteins in UT7/Epo-S1 cells transfected with
each of three full-length clones (pB19-M20, pB19-FL or pB19-
HG1) were compared using immunoblot analysis and immuno-
fluorescence (IF) staining. For pB19-M20 and pB19-HG1, an
expression level of the viral capsid protein was slightly lower
than in the cells transfected with pB19-FL (Fig. 5A). When
transfected UT7/Epo-S1cells were examined by IF staining with
a monoclonal antibody specific for the viral capsid, the capsid
proteins were detected in both nucleus and cytoplasm at 48 h
post-transfection (Fig. 5B). No difference was found among the
cells transfected with different plasmids.
VP1u PLA2 activity is critical for the infectivity of full-length
B19 clones
Comparison of amino acid sequences of capsid proteins
among the three full-length B19V clones revealed a substitutionFig. 5. Comparison of B19V capsid production following transfection of UT7/
Epo-S1 cells with B19V full-length genomic clones. (A) Detection of the B19V
VP2 capsid protein by immunoblotting. The samples were collected at 72 h post-
transfection and tested by immunoblotting with MAB 8293 antibody to the viral
capsid protein. Bands were visualized by chemiluminescence. (B) Detection of
B19V capsid proteins by IF staining. UT7/Epo-S1 cells were transfected with
pB19-M20, pB19-HG1 or pB19-FL, respectively. At 72 h post-transfection, the
capsid proteins were detected using MAB 521-5D antibody and then FITC-
labeled goat anti-mouse IgGs. Magnification ×750.(E176K) in pB19-FL (Table 1), which resulted from a nucleotide
point mutation (G3148A) of pB19-FL (corresponding to nt 3149
of pB19-M20) and is next to the catalytic residues of the PLA2-
like motif (Zadori et al., 2001) in the VP1u region. This mutation
is unique to the pB19-FL clone and was not found in the B19V
sequences which are available in the GenBank. Since the E176K
substitution identified in pB19-FL clone was proximate to the
catalytic residues of the PLA2-like motif in the VP1u region, we
tested the impact of the mutation on enzyme activity of PLA2 by
constructing a mutant based on the VP1u region of pB19-M20,
in which the E176 was altered to K. In addition, to confirm
the importance of conserved amino acid residues in theTable 2
Impact of mutations in PLA2 enzyme activity and B19V infectivity
Protein Mutagenesis site a PLA2 activity
b Relative infectivity c
μmol/min/ml %
VPlu (pB19-M20) 0.187 100
P133R C to G at nt 3021 0.001 20
H153A C to G at nt 3080 0.005 62
A to C at nt 3081
A174G C to G at nt 3144 0.001 2.1
D175A A to C at nt 3147 0.001 1.2
E176Kd G to A at nt 3149 0.005 20
bv sPLA2 0.63 0.63
TBS 0
Result shown are the mean values for three independent experiments.
a Nucleotide numbers are based on the sequence of the J35 isolate (GenBank
accession no. AY386330).
b Measured by the colorimetric kit. Protein concentration tested: recombinant
proteins (VPlu, PI33R, HI53R, AI74G, DI75A and EI76K), 20 μg; bee venom
(bv) secreted PLA2, 10 ng.
c Relative infectivity ¼ MT:fold change of viral transcript of day 0 vs day 3 postinfectionWT:fold change of viral transcript of day 0 vs day 3 postinfection 100k
d Mutation EI76K converted the VPlu of pB19-M20 to pB19-FL.
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additional VP1u mutants, including P133R, H153A, A174G and
D175A, were made and tested for their PLA2 activities. All of the
mutations in the Ca2+-binding loop and enzymatic catalytic sites
that were tested abolished PLA2 activity (Table 2). In contrast
to the wild-type (pB19-M20), PLA2 activity was completely
abolished when the E176K substitution identified in pB19-FL
was introduced into the VP1u region of pB19-M20.
In order to test the impact of the PLA2 activity on infectivity
of B19V full-length clone, mutations P133R, H153A, A174G,
D175A or E176K were introduced into the B19V infectious
clone (pB19-M20). The five mutants were termed pB19-M20/
PLA2-P133R, pB19-M20/PLA2-H153A, pB19-M20/PLA2-
A174G, pB19-M20/PLA2-D175A and pB19-M20/PLA2-
E176K. After transfection of these mutants into UT7/Epo-S1
cells, the supernatants prepared from the cell lysates of trans-
fected cells were used to infect CD36+ erythroid progenitor cells
(CD36+ EPCs), and infectivity was quantitatively analyzed by
real-time RT-PCR for the transcripts of the viral NS gene. In
comparison with pB19-M20, the wild-type infectious clone,
only 21% of relative infectivity was retained in the pB19-M20/
PLA2-E176K. Moreover, the relative infectivity of B19V mu-
tants of pB19-M20/PLA2-P133R, pB19-M20/PLA2-H153A,
pB19-M20/PLA2-A174G and pB19-M20/PLA2-D175A was
decreased to 21, 62, 2.1, and 1.2%, respectively. Taken together,
our data suggest that decreasing enzyme activity of PLA2 due to
the E176K mutation attenuated B19 viral infectivity. We also
confirmed that VP1u-PLA2 activity is critical to the infectivity of
full-length B19V clones.
VP1u-PLA2 mutation (E176K) identified in the native B19V
NAN isolate
To exclude the possibility that the nucleotide point mutation
(G3148A) of B19-FL clone was artifactually generated in theFig. 6. Comparison of infectivity of the B19V J35 isolate and NAN isolates by
real-time RT-PCR. The cells were inoculated with 50 genome copies/cell of
virus. Total RNA was extracted from the cells at 0, 24, 48 and 72 h post-
inoculation. The abundance of viral NS transcripts was measured by real-time
RT-PCR. Quantitations are given as copy numbers of NS transcripts/μl of cDNA
reaction. Results shown are mean values from three independent experiments.process of cloning, the VP1u region was PCR-amplified from a
DNA sample of the patient serum (NAN) from which pB19-FL
had been cloned. After TA cloning, inserts of 20 plasmids were
sequenced: all contained the G3148A mutation, indicating that
this mutation was carried in the original B19 virus. To compare
the infectivity of the NAN isolate with the J35 isolate, the
diluted patient sera containing similar numbers of B19V
genome copies (108 copies/ml) were inoculated into UT7/
Epo-S1 cells. Viral replication was evaluated by real-time PCR
for viral capsid transcripts. At 72 h post-inoculation, the viral
NS transcripts produced in the cells inoculated with the NAN
isolate were approximately 100-fold less than those with the J35
isolate Fig. 6. In comparison with B19V J35 isolate, the relative
infectivity of the NAN isolate was only 0.2%, indicating a
marked attenuation of infectivity in the NAN isolate.
Discussion
The availability of three full-length B19V genomic clones
(pB19-M20, pB19-FL and pB19-HG1) permitted a systematic
elucidation of molecular determinants of B19V pathogenicity.
Clone pB19-M20 had been previously shown to be able to
produce infectious virus after transfection into UT7/Epo-S1 cells
(Zhi et al., 2004, 2006). Using a similar approach, we demon-
strated that clone pB19-HG1 was infectious, but the infectivity
of pB19-FL was much lower in comparison with those of pB19-
M20 and pB19-HG1. Attenuated infectivity was also found in
native virus (the NAN isolate) from which the pB19-FL was
cloned. In order to determine why pB19-FL did not produce
infectious virus, three viral sequences were compared: in the
capsid region a nucleotide sequence difference, resulting in an
amino acid substitution (E176K) in the PLA2-like motif of the
VP1u, was observed. The recombinant VP1u protein bearing
this mutation had no catalytic activity compared with the wild-
type recombinant proteins. Moreover, when this mutation was
introduced into pB19-M20, there was a significant attenuation of
infectivity, confirming a critical role of the PLA2-like motif in
viral infectivity.
Although a total of eighteen substitutions were found in viral
proteins among pB19-M20, pB19-HG1 and pB19-FL, only
three were unique in pB19-FL. In addition to the PLA2 mutation
(E176K) identified in VP1u, F526L in the NS protein and A51V
in the X protein were present. Since no phenotypic change had
been found between pB19-M20 and pB19-HG1, these three
mutations unique for pB19-FL were likely responsible for the
attenuation of infectivity in pB19-FL. NS is a multifunctional
protein and plays important roles in regulation of the viral p6
promoter and DNA replication. The B19V NS sequence con-
tains a conserved helicase motif (amino acids 306–344) and a
putative NTP binding site (amino acids 326–393) (Momoeda
et al., 1994). We have previously shown that a NS-null mutant
was unable to replicate in permissive cells (Zhi et al., 2006).
In this study, Southern blot analysis demonstrated that the
replication form or newly synthesized viral DNA was detected
in all cells transfected with the three B19V clones, suggesting
that the substitution F526L in NS of pB19-FL had no impact on
viral replication. No difference had been found between the
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and viral DNA replication (Zhi et al., 2006). Therefore, it is
unlikely that the substitution A51V in the X protein had a
significant impact on viral infectivity of pB19-FL.
We have reported that a VP1-null mutation completely
abolished the infectivity of B19 virus (Zhi et al., 2006). The
minor capsid protein, VP1, differs from VP2 only in the VP1u
region composed of an additional 227 amino acids (Ozawa and
Young, 1987). The main neutralizing epitopes of B19V are in
VP1u region (Saikawa et al., 1993). Accessibility of the VP1u
region in native viral capsids required a conformation change
induced by acidification in vitro or cell-mediated stimulus during
viral entry (Ros et al., 2006). Recently, a conserved PLA2-like
motif (HDXXY) was identified in the N-terminal extension of the
VP1u region of members of the Parvoviridae (Zadori et al., 2001;
Canaan et al., 2004), including B19V (Dorsch et al., 2002; Lu
et al., 2006). Several amino acids in the highly conserved domain
of the VP1u region share homologies to the Ca2+-binding
loop and catalytic site of secreted PLA2. The residue P133 in the
Ca2+-binding loop, andH152, D153 andD175 in the catalytic site
of B19V PLA2 that corresponds to P21, H41, D42 and D63 in
porcine parvovirus (PPV) are highly conserved in the PLA2-like
motif found in members of Parvoviridae. In PPV, mutation in
these critical amino acid residues resulted in loss of PLA2 activity
and viral infectivity. In the present study, we constructed five
PLA2 mutants based on the B19V infectious clone (pB19-M20):
the P133Rmutant (the Ca2+-binding loop), the H153A,A174G or
D175A mutant (the enzyme catalytic site) or the E176K mutant
(the VP1u region present in pB19-FL clone). The infectivity of
viruses carrying these PLA2 mutations was significantly atten-
uated, with relative infectivity ranging from 2 to 62%, implicating
an important role of PLA2 in the VP1 protein in the B19V life
cycle. Although data obtained by in vitro PLA2 activity assay
showed that all mutations abolished the PLA2 activity, the results
of the infection assay revealed that the infectivity of viruses
derived from these B19V mutant clones appeared to be variable.
The viruses derived from two B19V infectious clones carrying
point mutations in the enzyme catalytic site (A174G or D175A)
completely lost infectivity. However, although PLA2 enzyme
activity was significantly decreased, viruses containing the point
mutation P133R in the Ca2+-binding loop and another mutation
H153A in the enzyme catalytic site retained 21% and 62% of
infectivity, respectively, in comparison with the wild-type infec-
tious clone, pB19-M20. Similarly, viruses having the point muta-
tion E176K were attenuated and retained only 21% of infectivity.
Although E176 was less conserved, in comparison with other
amino acid residues in the catalytic motif, conversion of an acidic
residue (E) to a basic residue (K) likely disturbs the molecular
structure of the enzyme. The attenuation of viral infectivity did not
completely correlate with the reduction of PLA2 enzyme activity
of these mutants when tested by the in vitro assay. Although we
cannot exclude the possibility that the VP1 unique region might
have additional functions, the phenomena observed in our study
likely implies a complexity of in vivo environment in which
certain cellular factors may compensate for viral PLA2 enzyme
activity, and therefore help to retain the infectivity of these
mutants to some degree. In order to test if the infectivity of theNAN isolate could be rescued by changing the VP1 unique region
sequence to the wild-type sequence, we attempted to correct the
E176K mutation in the VP1 unique sequence of pB19-FL (clone
of NAN isolate) by insertion of the corrected sequence into the
pB19-clone. However, due to the instability of the genome in the
plasmid backbone, wewere never been able to rescue a full-length
corrected genome, and have therefore been unable to test the
construct.
In immunocompetent individuals, B19V infection may be
associated with arthralgia and arthropathy. The PLA2-like motif
in the exposed VP1u region may have a direct role in initiating
and/or accelerating the inflammatory response in the synovial
tissue and thus contributes to B19-associated arthropathy (Lu
et al., 2006; Zadori et al., 2001). Studies of the original serum
sample that was used as the source for cloning pB19-FL con-
firmed that the PLA2 (E176K) mutant was present in the native
virus (the NAN isolate). The B19V NAN isolate was identified
in an individual without symptom of viral infection. The serum
was found by real-time PCR to contain ~108 genome copies of
B19/ml, much less than that of J35 (3.3×1013 genome copies/
ml (Wong and Brown, 2006). The relative infectivity of the
NAN isolate versus the J35 isolate was approximately 0.2%.
The attenuation of the B19V NAN isolate for both viral repli-
cation and infectivity was at least partially due to the mutation in
the PLA2-like motif of its capsid protein. This naturally atten-
uated B19V could be an important candidate in development of
an attenuated vaccine against B19V infection.
Materials and methods
Cells and viruses
UT7/Epo-S1 cells, a subclone of UT7/Epo (Shimomura et
al., 1992) previously reported to have an increased sensitivity
for parvovirus B19 were kindly provided by Kazuo Sugamura
(Tohoku University Graduate School of Medicine, Japan). The
cells were maintained in Iscove's modified Dulbecco's medium
(IMDM, Mediatech, Herndon, VA) containing 10% fetal calf
serum (FCS), 2 U/ml recombinant human (rhu) erythropoietin
(Epo, Amgen, Thousand Oaks, CA) and antibiotics.
Human CD36+ EPCs which are fully permissive for B19V
infection were generated from G-CSF mobilized CD34+ periph-
eral blood stems cells. The cells were cultured in a serum-free
expansion medium containing a 1:5 dilution of BIT 9500 (Stem
Cell Technologies, Vancouver, British Columbia, Canada) in
alpha minimum essential medium (AMEM, Mediatech), obtain-
ing a final concentration of 10 mg/ml of BSA, 10 μg/ml of rhu
insulin, 200 μg/ml of iron-saturated human transferrin, 900 ng/ml
of ferrous sulfate (Sigma, St. Louis, MO), 90 ng/ml of ferric
nitrate (Sigma), 10 nM hydrocortisone (Sigma), 100 ng/ml of rhu
SCF (Stem Cell Technologies), 5 ng/ml of rhu IL-3 (R&D
Systems, Minneapolis, MN) and 3 U/ml of rhu EPO (Amgen).
The B19V J35 isolate (GenBank Accession no. AY386330)
(Zhi et al., 2004), was obtained from the serum of a child with
sickle cell anemia undergoing aplastic crisis and sent to the
National Institutes of Health for diagnostic purposes. The serum
was found to contain 3.3×1013 genome copies of B19/ml by
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isolate (GenBank Accession no. AY504945), which was
provided by Bernard Cohen (Health Protection Agency,
London, UK), was obtained from a UK patient with asympto-
matic B19V infection as part of a large scale screening of blood
donors. The serum was found to contain ~108 genome copies of
B19/ml by real-time PCR.
Cloning and sequencing of parvovirus B19 full-length genomic
clones
Three full-length clones for parvovirus B19 were obtained
from different sources. The plasmid pB19-M20 was constructed
by separately cloning two halves of the virus resulting from a
unique BamHI digestion; the halves were subsequently ligated
to obtain the full-length B19V genome. pB19-M20 containing
the full-length B19V genome of the J35 isolate has been proven
to be infectious in our previous study (Zhi et al., 2004).
For pB19-HG1, the ITR and coding region of B19V genome
were first PCR-amplified and separately cloned. After BssHII
digestion, the fragments were joined together to form the full-
length B19V genome. pB19-HG1 contained full-length B19V
genome of the HV isolate (GenBank Accession no. AF162273).
For pB19-FL, B19V genome was digested with BssHII,
ligated to the pLITMUS29 vector (New England Biolabs, MA)
and transformed into competent DH5α cells (Brunstein et al.,
2000). A positive clone, containing nt 185–5413 of B19V, was
cut in half with BamHI. The missing 184 nt ends of the hairpins
were synthesized as two pairs of 70–114 nt long oligos (with
11-nt overlaps in the middle and with BssHII and EcoRI sites at
the inner and outer ends, respectively) for each end of the
genome, which were annealed to each other and ligated to each
half of the B19 clone. The final full-length B19V clone was
obtained by joining the two genome halves by ligation of the
excised left half into the plasmid containing the right half.
pB19-FL contained full-length B19V genome of the NAN
isolate.
Three different full-length B19V genomes cloned in the
plasmids were sequenced using the BigDye terminator cycle
sequencing kit (ABI-Perkin Elmer, Foster City, CA). The full-
length sequences of both strands were obtained by primer
walking. All DNA sequences and amino acid sequences of
ORFs were analyzed using the Lasergene software (DNAStar,
Inc., Madison, WI). DNA pairwise homology was determined
by the Lipman–Pearson method with a Ktuple of 2, gap penalty
of 4, and deletion penalty of 12. Multiple sequence align-
ments were performed by the Megalign program, using the
Clustal method with a gap penalty of 10 and gap length penalty
of 10.
Infection and transfection
For infection studies, 2×104 of UT7/Epo-S1 cells in 10 μl of
IMDM were mixed with an equal volume of diluted viremic
serum (J35 or NAN serum was diluted to contain 108 B19V
genome copies/ml) and incubated at 4 °C for 2 h to allow for
maximum virus–cell interaction. The cells were then diluted to2×105 cells/ml in the culture medium, and incubated at 37 °C in
5% CO2. Cells were harvested on day 3 post-infection and
tested for evidence of infection by detection of viral transcripts
and protein production.
Transfection of the UT7/Epo-S1 cells was performed as
previously described (Zhi et al., 2004). The full-length B19
genome was released from the plasmids by restriction enzyme
digestions with SalI (pB19-M20), EcoRI (pB19-FL) or BsaBI
(pB19-HG1). The DNA fragments were separated by agarose gel
electrophoresis, and the 5.6-kb B19V genome was excised and
purified by using the QIAEX II Gel Extract kit (QIAGEN, Santa
Clarita, CA). The cells (2×106) were transfected with 5 µg of
purified B19 DNA using the AMAXA Cell Line Nucleofector™
kit (Amaxa, Gaithersburg, MD). The cells were harvested at
various times post-transfection, and used for infection, DNA,
RNA and immunofluorescence (IF) studies. For infection study,
cells were harvested at 72 h post-transfection, washed free of
inoculums using fresh culture medium, and cell lysate was
prepared by three cycles of freeze/thaw. After centrifugation at
10,000 ×g for 10 min, a clarified supernatant was treated with
RNase at a final concentration of 1 U/μl (Roche, Roswell, GA).
UT7/Epo-S1 cells or CD36+ EPCs (2×104) in 10 μl of culture
medium were mixed with an equal volume of the clarified
supernatant and incubated at 4 °C for 2 h to allow for maximum
virus–cell interaction. The cells were then diluted to 2×105 cells/
ml in the culture medium, and incubated at 37 °C in 5% CO2.
Cells were harvested on day 3 post-infection and tested for
evidence of infection by detection of viral transcripts and protein
expression.
RT-PCR and real-time RT-PCR
Total RNA was extracted from UT7/Epo-S1 cells (2×105)
using RNA STAT60 (Tel-Test Inc., Friendswood, TX). Residual
DNAwas removed byDNase I (Promega,MadisonWI) treatment
at a final concentration of 90 U/ml for 15 min at room temper-
ature. RNAwas converted to cDNA using random hexamers and
SuperScript II (Invitrogen, Carlsbad, CA), and RT-PCR for the
spliced capsid transcripts was performed with primers B19-1 and
B19-9 as previously described (Nguyen et al., 2002).
RNA transcripts were quantitated by real-time RT-PCR de-
signed to amplify products in the NS regions using the QuantiTect
Probe RT-PCR kit (Qiagen, Valencia, CA) as previously de-
scribed (Wong and Brown, 2006). QuantiTect Probe RT-PCR
master mix and QuantiTect RT mix were combined with 0.4 μM
of the NS amplification primers (5′-GTTTTATGGGCCGCCA-
AGTA-3′ and 5′-ATCCCAGACCACCAAGCTTTT-3′) and
0.2 μM NS probe (5′-FAM-CCATTGCTAAAAGTGTTCCA-
BHQ1-3′). After an initial activation step of 15 min at 95 °C, 45
cycles of 15 s at 94 °C and 60 s at 60 °C were performed. The
number of transcripts was estimated by comparison of the cDNA
copy numbers with a standard curve of serial dilutions of pYT103
(Shimomura et al., 1992). To confirm extraction of RNA, and to
normalize the numbers of transcripts per cell, real-time RT-PCR
was performed using the same amplification condition, but with
β-actin primers (5′-CACCCAGCACAATGAAG-3′ and 5′-
GATCCACACGGAGTACT-3′) and β-actin probe (5′-JOE-
451C. Filippone et al. / Virology 374 (2008) 444–452TCAAGATCATTGCTCCTCCTGAGCGC-BHQ-3′). A β-actin
standard curve was obtained from serial dilutions of a plasmid
containing an extended region of the β-actin-coding sequence.
Southern blot analysis of B19V DNA
DNA was extracted from transfected UT7/Epo-S1 cells
(5×105) as previously described (Shimomura et al., 1992).
Briefly, 5×105 cells were incubated with 100 mM NaCl,
10 mM Tris–HCl, pH 7.5, 0.5% sodium dodecylsulfate, 5 mM
EDTA, and 200 μg/ml proteinase K overnight at 37 °C,
followed by phenol–chloroform extraction. For some experi-
ments high and low-molecular weight DNAs were separated by
the Hirt method (Hirt, 1967). Purified DNA (400 ng) was
digested with 20 U of BamHI (a single cut in B19) or EcoRI (no
cut in B19) at 37 °C for 4 h, the fragments were then separated
by agarose gel electrophoresis, transferred to a nylon membrane
(Nylon+, Amersham, Piscataway, NJ), and hybridized with a
32P-random-primed probe of the complete B19V coding region
as previously described (Shimomura et al., 1992).
Immunoblot analysis and immunofluorescence staining of
B19V capsid proteins
The procedure for immunoblotting was essentially the same as
described elsewhere (Zhi et al., 1997). Briefly, cells were harvested
at 72 h post-transfection and proteins were separated by 10%SDS-
PAGE. The separated proteins were transferred to a nitrocellulose
membrane (Invitrogen) and then blocked with Tris-buffered saline
(TBS) buffer (150 mM NaCl, 50 mM Tris–HCl, pH 7.4)
containing 5% milk and 0.05% Tween 20 at room temperature
for 2 h to saturate protein-binding sites. Antigens were detected by
incubation of the membrane with mouse monoclonal antibody
MAB 8293 (Millipore Corporation, Billerica, MA) (1:1000
dilutions) to B19V capsid proteins, followed by incubation with
peroxidase-conjugated anti-mouse antibody (1:100,000 dilutions;
BD Biosciences Clontech, Palo Alto, CA). Bands were visualized
by incubating the membrane with the SuperSignal chemilumines-
cent reagent (Pierce, Rockford, IL), and then exposing it to an
X-ray film. The densities of detected bands were analyzed with
a PhosphorImager (Molecular Dynamics, Sunnyvale, CA).
For IF staining, transfected cells were harvested and cyto-
centrifuged at 750×g for 8 min in a cytospin funnel (Shandon,
Pittsburgh PA). The cells were fixed in acetone:methanol (1:1) at
−20 °C for 5 min, washed twice in phosphate buffered saline
(PBS), and incubated with mouse monoclonal antibody MAB
521-5D (Millipore Corporation) to conformational epitope of
B19V capsid protein in PBSwith 10%FCS for 1 h at 37 °C. For IF
staining, a fluorescein isothiocyanate (FITC)-labeled goat anti-
mouse IgG (BD Biosciences Clontech) was used as secondary
antibody.
Cloning, site mutagenesis, expression, and purification of
VP1u-region protein
The full-length VP1u region was cloned into a pET ex-
pression vector (Invitrogen) with V5 and 6× His epitopes at thecarboxyl terminus. To obtain mutations in the PLA2 motif of
VP1u, site-directed mutagenesis was performed with the
QuikChange Site-Directed Mutagenesis kit in accordance with
the manufacturer's instructions (Stratagene, La Jolla, CA). All
proteins were expressed in Escherichia coli BL21 Star strain
(Invitrogen), after induction with 1 mmol/l isopropyl-β-D-1-
thiogalactopyranoside for 5 h, and purified using the His Bind
Purification kit (Novagen, San Diego, CA). The soluble purified
proteins were dialyzed against TBS and concentrated using the
Centriplus concentrator (10-kDa exclusion limit; Millipore) to
give a final concentration of ~2 mg/ml.
PLA2 catalytic activity
Recombinant B19V proteins were assayed for PLA2 activity
by the use of the PLA2 Activity kit in accordance with the
manufacturer's instructions (Cayman Chemical, Ann Arbor,
Michigan), with dynamic colorimetric measurements (the optical
density at 405 nm) determined every minute for 10 min. Results
are expressed as micromoles per minute per milliliter.
Generation of B19V mutant genomes based on the infectious
clones
The mutations of VP1u region were produced by site-
directed mutagenesis of pB19-M20. Due to the instability of the
ITRs, it was not possible to perform direct mutagenesis on
plasmids containing the intact ITR sequences. Therefore, the
B19V DNA fragments of interest were first subcloned into a
plasmid vector and, after successful mutagenesis, were then
reinserted into pB19-M20 as described in our previous study
(Zhi et al., 2006). All final constructs were sequenced to con-
firm no unexpected mutation arisen from the processes of
mutagenesis and cloning.
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